Jeremy Wohlwend

Jeremy Wohlwend and Gabriele Corso, co-founders of Boltz, delve into the transformative power of AI in molecular biology. They discuss Boltz’s mission to create open-source models that revolutionize biomolecular interaction and drug discovery. The conversation highlights breakthroughs post-AlphaFold, the rapid adoption of Boltz models by the pharma sector, and the launch of Boltz Lab—designed to streamline protein and small-molecule design in scientific workflows. They envision a future where AI accelerates iteration and enhances the drug discovery process.